About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
PMID: 33893449 Journal: EUROPEAN JOURNAL OF CLINICAL NUTRITION Year: 2021 Reference: Eur J Clin Nutr. 2021 Sep;75(9):1368-1382. doi: 10.1038/s41430-021-00913-6. Epub 2021 Apr 23. Impact factor: 4.016 Publication type: Paper in international publication Authors: Domenech, Eugeni, Julia, Antonio, Martinez-Mateu, Sergio H, Blanco, Francisco, Gratacos, Jordi, Blanco, Ricardo, Taboada, Victor Martinez, Fernandez, Emilia, Unamuno, Pablo, Gonzalez, Isidoro et al. DOI: 10.1038/s41430-021-00913-6
PMID: 33882889 Journal: BMC MUSCULOSKELETAL DISORDERS Year: 2021 Reference: BMC Musculoskelet Disord. 2021 Apr 21;22(1):372. doi: 10.1186/s12891-021-04248-y. Impact factor: 2.355 Publication type: Paper in international publication Authors: Julia, Antonio, Lopez-Lasanta, Maria, Blanco, Francisco, Gomez, Antonio, Haro, Isabel, Mas, Antonio Juan, Erra, Alba, Vivar, Ma Luz Garcia, Monfort, Jordi, Sanchez-Fernandez, Simon et al. DOI: 10.1186/s12891-021-04248-y
PMID: 33884956 Journal: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY Year: 2021 Reference: J Investig Allergol Clin Immunol. 2021 Apr 22:0. doi: 10.18176/jiaci.0696. Impact factor: 7.033 Publication type: Paper in international publication Authors: Vila, L, Ibanez-Sandin, M D, Rodriguez Del Rio, P, Alvarado, M I, Garcia, B E, Garriga-Baraut, T, Reche Frutos, M, Escudero, C, Ramirez, A, Marchan-Martin, E et al. DOI: 10.18176/jiaci.0696
PMID: 33880889 Journal: CLINICAL AND EXPERIMENTAL ALLERGY Year: 2021 Reference: Clin Exp Allergy. 2021 Aug;51(8):1033-1045. doi: 10.1111/cea.13884. Epub 2021 May 11. Impact factor: 5.018 Publication type: Paper in international publication Authors: Bousquet, Jean, Schroder-Bernhardi, Detlef, Bachert, Claus, Costa, Elisio M, Czarlewski, Wienczyslawa, Devillier, Philippe, Fonseca, Joao, Klimek, Ludger, Kuna, Piotr, Lourenco, Olga et al. DOI: 10.1111/cea.13884
PMID: 30660771 Journal: AMERICAN JOURNAL OF OPHTHALMOLOGY Year: 2019 Reference: Am J Ophthalmol. 2019 Apr;200:85-94. doi: 10.1016/j.ajo.2018.12.019. Epub 2019 Jan 17. Impact factor: 4.483 Publication type: Paper in international publication Authors: Modesto, Consuelo, Gonzalez-Vela, Carmen, Pablo-Demetrio, Rosalia, Aurrecoechea, Elena, Cordero, Miguel, Dominguez-Casas, Lucia C, Atienza-Mateo, Belen, Martin-Varillas, Jose Luis, Loricera, Javier, Palmou-Fontana, Natalia et al. DOI: 10.1016/j.ajo.2018.12.019
PMID: 30655091 Journal: SEMINARS IN ARTHRITIS AND RHEUMATISM Year: 2019 Reference: Semin Arthritis Rheum. 2019 Aug;49(1):126-135. doi: 10.1016/j.semarthrit.2019.01.003. Epub 2019 Jan 5. Impact factor: 5.072 Publication type: Paper in international publication Authors: Loricera, Javier, Aldasoro, Vicente, Castaneda, Santos, Villa, Ignacio, Humbria, Alicia, Moriano, Clara, Romero-Yuste, Susana, Narvaez, Javier, Gomez-Arango, Catalina, Perez-Pampin, Eva et al. DOI: 10.1016/j.semarthrit.2019.01.003
PMID: 30654196 Journal: Journal of Allergy and Clinical Immunology-In Practice Year: 2019 Reference: J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15. Impact factor: 7.55 Publication type: Paper in international publication Authors: Nunez-Cordoba, Jorge M, Baeza, Maria Luisa, Echechipia, Susana, Gaig, Pere, Garcia, Blanca Esther, Labrador-Horrillo, Moises, Sala-Cunill, Ana, Bresco, Marina Sabate, Beristain, Ana, Quinones, Dolores et al. DOI: 10.1016/j.jaip.2018.12.025
PMID: 30273710 Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Year: 2019 Reference: J Allergy Clin Immunol. 2019 Jan;143(1):359-368. doi: 10.1016/j.jaci.2018.09.009. Epub 2018 Sep 29. Impact factor: 14.11 Publication type: Paper in international publication Authors: Balderrama-Rodriguez, Angelica, Ramos, Eduardo, Modesto, Consuelo, Mesa-Del-Castillo, Pablo, Ortego-Centeno, Norberto, Clemente, Daniel, Souto, Alejandro, Palmou, Natalia, Remesal, Agustin, Leslie, Kieron S et al. DOI: 10.1016/j.jaci.2018.09.009
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
